Neuphoria Therapeutics confirmed it is in discussions with London-listed Scancell Holdings about a potential acquisition of Neuphoria by Scancell, with Scancell becoming a Nasdaq-listed company after any deal. The statement follows an earlier announcement by Scancell about a possible combination, made after UK press speculation and in compliance with UK regulations. Neuphoria cautioned that there is no certainty an agreement will be reached, nor on the terms or whether a transaction will proceed. Any further announcements will be made in line with SEC and Nasdaq rules.
Neuphoria Therapeutics IncPotential acquisition by Scancell, which would result in Nasdaq listing, is a positive capital event for Neuphoria.
Scancell Hldgs PlcScancell is in talks to acquire Neuphoria and become Nasdaq-listed, a positive M&A and listing development.